New approaches to the management of schizophrenia: Focus on aberrant hippocampal drive of dopamine pathways

Drug Design, Development and Therapy

Volumn 8, Issue , 2014, Pages 887-896

  Perez, Stephanie M ^a   Lodge, Daniel J ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

Dopamine; GABA; Glutamate; Hippocampus; MAM rat; Schizophrenia

Indexed keywords

4 AMINOBUTYRIC ACID; ATYPICAL ANTIPSYCHOTIC AGENT; CHLORPROMAZINE; DOPAMINE; GLUTAMIC ACID; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NEUROLEPTIC AGENT;

BRAIN DEPTH STIMULATION; BRAIN REGION; CELL THERAPY; DOPAMINERGIC SYSTEM; DRUG EFFECT; ELECTROENCEPHALOGRAM; EXECUTIVE FUNCTION; GABAERGIC SYSTEM; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC RISK; GENETIC VARIABILITY; HERITABILITY; HIPPOCAMPUS; HUMAN; NEGATIVE SYNDROME; NEUROTRANSMISSION; NONHUMAN; PROTEIN EXPRESSION; REVIEW; SCHIZOPHRENIA; SIGNAL TRANSDUCTION; TREATMENT PLANNING; WORKING MEMORY; ALLOSTERISM; ANIMAL; BIOLOGICAL THERAPY; DRUG DESIGN; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; PROCEDURES; RAT;

ALLOSTERIC REGULATION; ANIMALS; ANTIPSYCHOTIC AGENTS; CELL- AND TISSUE-BASED THERAPY; DEEP BRAIN STIMULATION; DOPAMINE; DRUG DESIGN; GAMMA-AMINOBUTYRIC ACID; GLUTAMIC ACID; HIPPOCAMPUS; HUMANS; RATS; SCHIZOPHRENIA;

EID: 84903904315     PISSN: 11778881     EISSN: None     Source Type: Journal    
DOI: 10.2147/DDDT.S42708     Document Type: Review

References (138)

1. McGrath J, Saha S, Welham J, El Saadi O, MacCauley C, Chant D. A systematic review of the incidence of schizophrenia: the distribution of rates and the influence of sex, urbanicity, migrant status and methodology. BMC Med. 2004; 2: 13.
2. Stilo SA, Murray RM. The epidemiology of schizophrenia: replacing dogma with knowledge. Dialogues Clin Neurosci. 2010; 12: 305-315.
3. DeLisi LE. The significance of age of onset for schizophrenia. Schizophren Bull. 1992; 18: 209-215.
4. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, etal. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005; 353(12): 1209-1223.
5. Carpenter WT Jr, Buchanan RW. Schizophrenia. N Engl J Med. 1994; 330(10): 681-690.
6. Carlsson A, Lindqvist M. Effect of chlorpromazine or haloperidol on formation of 3methoxytyramine and normetanephrine in mouse brain. Acta Pharmacol Toxicol. 1963; 20: 140-144.
7. Andén NE, Butcher SG, Corrodi H, Fuxe K, Ungerstedt U. Receptor activity and turnover of dopamine and noradrenaline after neuroleptics. Eur J Pharmacol. 1970; 11(3): 303-314.
8. Stone JM, Raffin M, Morrison P, McGuire PK. Review: The biological basis of antipsychotic response in schizophrenia. J Psychopharmacol. 2010; 24(7): 953-964.
9. Conley RR, Buchanan RW. Evaluation of treatment-resistant schizophrenia. Schizophr Bull. 1997; 23(4): 663-674.
10. Hasan A, Falkai P, Wobrock T, Lieberman J, Glenthoj B, etal. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, part 1: update 2012 on the acute treatment of schizophrenia and the management of treatment resistance. World J Biol Psychiatry. 2012; 13: 318-378.
11. Hasan A, Falkai P, Wobrock T, Lieberman J, Glenthoj B, etal. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: update 2012 on the long-term treatment of schizophrenia and management of antipsychotic-induced side effects. World J Biol Psychiatry. 2013; 149(1): 2-44.
12. Javitt DC. Management of negative symptoms of schizophrenia. Curr Psychiatry Rep. 2001; 3(5): 413-417.
13. Tamminga CA, Buchanan RW, Gold JM. The role of negative symptoms and cognitive dysfunction in schizophrenia outcome. Int Clin Psychopharmacol. 1998; 13 Suppl 3: S21-S26.
14. Davé M. Clozapine-related tardive dyskinesia. Biol Psychiatry. 1994; 35(11): 886-887.
15. Ertugrul A, Demir B. Clozapine-induced tardive dyskinesia: a case report. Prog Neuropsychopharmacol Biol Psychiatry. 2005; 29(4): 633-635.
16. López-Muñoz F, Alamo C, Cuenca E, Shen WW, Clervoy P, Rubio G. History of the discovery and clinical introduction of chlorpromazine. Ann Clin Psychiatry. 2005; 17(3): 113-135.
17. Altschule MD. Use of chlorpromazine and reserpine in mental disorders. N Engl J Med. 1956; 254(11): 515-519.
18. Creese I, Burt DR, Snyder SH. Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. Science. 1976; 192(4238): 481-483.
19. Seeman P, Lee T. Antipsychotic drugs: direct correlation between clinical potency and presynaptic action on dopamine neurons. Science. 1975; 188(4194): 1217-1219.
20. Miyamoto S, Duncan GE, Marx CE, Lieberman JA. Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs. Mol Psychiatry. 2005: 10(1): 79-104.
21. Stevens JR. An anatomy of schizophrenia? Arch Gen Psychiatry. 1973; 29(2): 177-189.
22. Meltzer HY, Simonovic M, Gudelsky GA. Phencyclidine-induced inhibition of rat prolactin secretion: increased portal blood dopamine. Eur J Pharmacol. 1985; 110(1): 143-146.
23. Kane J, Honigfeld G, Singer J, Meltzer H. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry. 1988; 45(9): 789-796.
24. Meltzer HY. Clinical studies on the mechanism of action of clozapine: the dopamine-serotonin hypothesis of schizophrenia. Psychopharmacology (Berl). 1989; 99 Suppl: S18-S27.
25. Abi-Dargham A, Laruelle M. Mechanisms of action of second generation antipsychotic drugs in schizophrenia: insights from brain imaging studies. Eur Psychiatry. 2005; 20(1): 15-27.
26. Frankle WG, Gil R, Hackett E, etal. Occupancy of dopamine D2 receptors by the atypical antipsychotic drugs risperidone and olanzapine: theoretical implications. Psychopharmacology (Berl). 2004; 175(4): 473-480.
27. Bressan RA, Erlandsson K, Jones HM, etal. Is regionally selective D2/D3 dopamine occupancy sufficient for atypical antipsychotic effect? an in vivo quantitative [123I]epidepride SPET study of amisulpride-treated patients. Am J Psychiatry. 2003; 160(8): 1413-1420.
28. Kapur S, Remington G. Dopamine D(2) receptors and their role in atypical antipsychotic action: still necessary and may even be sufficient. Biol Psychiatry. 2001; 50(11): 873-883.
29. Seeman P. Atypical antipsychotics: mechanism of action. Can J Psychiatry. 2002; 47(1): 27-38.
30. Meltzer HY, McGurk SR. The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia. Schizophren Bull. 1999; 25(5): 233-255.
31. Marder SR, Davis JM, Chouinard G. The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials. J Clin Psychiatry. 1997; 58(12): 538-546.
32. Tollefson GD, Sanger TM. Negative symptoms: a path analytic approach to a double-blind, placebo-and haloperidol-controlled clinical trial with olanzapine. Am J Psychiatry. 1997; 154(4): 466-474.
33. Keefe RS, Silva SG, Perkins DO, Lieberman JA. The effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: a review and meta-analysis. Schizophr Bull. 1999; 25(2): 201-222.
34. Newcomer JW. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs. 2005; 19 Suppl 1: 1-93.
35. Jones PB, Barnes TR, Davies L, etal. Randomized controlled trial of the effect on Quality of Life of second-vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Arch Gen Psychiatry. 2006; 63(10): 1079-1087.
36. Leucht S, Cipriani A, Spineli L, etal. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet. 2013; 382(9896): 951-962.
37. Leucht S, Kissling W, Davis JM. Second-generation antipsychotics for schizophrenia: can we resolve the conflict?Psychol Med. 2009; 39(10): 1591-1602.
38. Howes OD, Kapur S. The dopamine hypothesis of schizophrenia: version III-the final common pathway. Schizophr Bull. 2009; 35(3): 549-562.
39. Laruelle M, Abi-Dargham A. Dopamine as the wind of the psychotic fire: new evidence from brain imaging studies. J Psychopharmacol. 1999; 13(4): 358-371.
40. Carlsson A, Waters N, Waters S, Carlsson ML. Network interactions in schizophrenia-therapeutic implications. Brain Res Brain Res Rev. 2000; 31(2-3): 342-349.
41. Abi-Dargham A. Do we still believe in the dopamine hypothesis? New data bring new evidence. Int J Neuropsychopharmacol. 2004; 7 Suppl 1: S1-S5.
42. Lieberman JA, Kane JM, Alvir J. Provocative tests with psychostimulant drugs in schizophrenia. Psychopharmacology (Berl). 1987; 91(4): 415-433.
43. Kegeles LS, Abi-Dargham A, Frankle WG, etal. Increased synaptic dopamine function in associative regions of the striatum in schizophrenia. Arch Gen Psychiatry. 2010; 67(3): 231-239.
44. Laruelle M, D'Souza CD, Baldwin RM, etal. Imaging D2 receptor occupancy by endogenous dopamine in humans. Neuropsychopharmacology. 1997; 17(3): 162-174.
45. Fujita M, Verhoeff NP, Varrone A, etal. Imaging extrastriatal dopamine D(2) receptor occupancy by endogenous dopamine in healthy humans. Eur J Pharmacol. 2000; 387(2): 179-188.
46. Egerton A, Chaddock CA, Winton-Brown TT, etal. Presynaptic striatal dopamine dysfunction in people at ultra-high risk for psychosis: findings in a second cohort. Biol Psychiatry. 2013; 74(2): 106-112.
47. McGowan S, Lawrence AD, Sales T, Quested D, Grasby P. Presynaptic dopaminergic dysfunction in schizophrenia: a positron emission tomographic [18F]fluorodopa study. Arch Gen Psychiatry. 2004; 61(2): 134-142.
48. Howes OD, Kambeitz J, Kim E, etal. The nature of dopamine dysfunction in schizophrenia and what this means for treatment. Arch Gen Psychiatry. 2012; 69(8): 776-786.
49. Meyer-Lindenberg A, Miletich RS, Kohn PD, etal. Reduced prefrontal activity predicts exaggerated striatal dopaminergic function in schizophrenia. Nat Neurosci. 2002; 5(3): 267-271.
50. Collins P, Roberts AC, Dias R, Everitt BJ, Robbins TW. Perseveration and strategy in a novel spatial self-ordered sequencing task for nonhuman primates: effects of excitotoxic lesions and dopamine depletions of the prefrontal cortex. J Cogn Neurosci. 1998; 10(3): 332-354.
51. Williams JM, Galli A. The dopamine transporter: a vigilant border control for psychostimulant action. Handb Exp Pharmacol. 2006, 215-232.
52. Harrison PJ. The neuropathology of schizophrenia. A critical review of the data and their interpretation. Brain. 1999; 122(Pt 4): 593-624.
53. Lodge DJ, Grace AA. Hippocampal dysregulation of dopamine system function and the pathophysiology of schizophrenia. Trends Pharmacol Sci. 2011; 32(9): 507-513.
54. Krystal JH, Karper LP, Seibyl JP, etal. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry. 1994; 51(3): 199-214.
55. Jentsch JD, Roth RH. The neuropsychopharmacology of phencyclidine: from NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia. Neuropsychopharmacology. 1999; 20(3): 201-225.
56. Javitt DC, Zukin SR. Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry. 1991; 148(10): 1301-1308.
57. Jenkins TA, Harte MK, Reynolds GP. Effect of subchronic phencyclidine administration on sucrose preference and hippocampal parvalbumin immunoreactivity in the rat. Neurosci Lett. 2010; 471(3): 144-147.
58. Moghaddam B, Adams BW. Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats. Science. 1998; 281(5381): 1349-1352.
59. Moghaddam B, Adams B, Verma A, Daly D. Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex. J Neurosci. 1997; 17(8): 2921-2927.
60. Sturgeon RD, Fessler RG, Meltzer HY. Behavioral rating scales for assessing phencyclidine-induced locomotor activity, stereotyped behavior and ataxia in rats. Eur J Pharmacol. 1979; 59(3-4): 169-179.
61. Sams-Dodd F. Distinct effects of d-amphetamine and phencyclidine on the social behaviour of rats. Behav Pharmacol. 1995; 6(1): 55-65.
62. Sams-Dodd F. Phencyclidine-induced stereotyped behaviour and social isolation in rats: a possible animal model of schizophrenia. Behav Pharmacol. 1996; 7(1): 3-23.
63. Noda A, Noda Y, Kamei H, etal. Phencyclidine impairs latent learning in mice: interaction between glutamatergic systems and sigma(1) receptors. Neuropsychopharmacology. 2001; 24(4): 451-460.
64. Egerton A, Brett RR, Pratt JA. Acute delta9-tetrahydrocannabinol-induced deficits in reversal learning: neural correlates of affective inflexibility. Neuropsychopharmacology. 2005; 30(10): 1895-1905.
65. Wang CZ, Yang SF, Xia Y, Johnson KM. Postnatal phencyclidine administration selectively reduces adult cortical parvalbumin-containing interneurons. Neuropsychopharmacology. 2008; 33(10): 2442-2455.
66. Mohn AR, Gainetdinov RR, Caron MG, Koller BH. Mice with reduced NMDA receptor expression display behaviors related to schizophrenia. Cell. 1999; 98(4): 427-436.
67. Csicsvari J, Hirase H, Czurko A, Buzsáki G. Reliability and state dependence of pyramidal cell-interneuron synapses in the hippocampus: an ensemble approach in the behaving rat. Neuron. 1998; 21(1): 179-189.
68. Maccaferri G, Dingledine R. Control of feedforward dendritic inhibition by NMDA receptor-dependent spike timing in hippocampal interneurons. J Neurosci. 2002; 22(13): 5462-5472.
69. Théberge J, Bartha R, Drost DJ, etal. Glutamate and glutamine measured with 4.0 T proton MRS in never-treated patients with schizophrenia and healthy volunteers. Am J Psychiatry. 2002; 159(11): 1944-1946.
70. Lewis DA, Hashimoto T, Volk DW. Cortical inhibitory neurons and schizophrenia. Nat Rev Neurosci. 2005; 6: 312-324.
71. Benes FM, Berretta S. GABAergic interneurons: implications for understanding schizophrenia and bipolar disorder. Neuropsychopharmacology. 2001; 25(1): 1-27.
72. Lewis DA, Curley AA, Glausier JR, Volk DW. Cortical parvalbumin interneurons and cognitive dysfunction in schizophrenia. Trends Neurosci. 2012; 35(1): 57-67.
73. Curley AA, Lewis DA. Cortical basket cell dysfunction in J Physiol. 2012; 590(Pt 4): 715-724.
74. Curley AA, Eggan SM, Lazarus MS, Huang ZJ, Volk DW, Lewis DA. Role of glutamic acid decarboxylase 67 in regulating cortical parvalbumin and GABA membrane transporter 1 expression: implications for schizophrenia. Neurobiol Dis. 2013; 50: 179-186.
75. Gonzalez-Burgos G, Lewis DA. NMDA receptor hypofunction, parvalbumin-positive neurons, and cortical gamma oscillations in schizophrenia. Schizophr Bull. 2012; 38(5): 950-957.
76. Beasley CL, Zhang ZJ, Patten I, Reynolds GP. Selective deficits in prefrontal cortical GABAergic neurons in schizophrenia defined by the presence of calcium-binding proteins. Biol Psychiatry. 2002; 52(7): 708-715.
77. Beneyto M, Morris HM, Rovensky KC, Lewis DA. Lamina-and cell-specific alterations in cortical somatostatin receptor 2 mRNA expression in schizophrenia. Neuropharmacology. 2012; 62(3): 1598-1605.
78. Hashimoto T, Volk DW, Eggan SM, etal. Gene expression deficits in a subclass of GABA neurons in the prefrontal cortex of subjects with schizophrenia. J Neurosci. 2003; 23(15): 6315-6326.
79. Woo TU, Whitehead RE, Melchitzky DS, Lewis DA. A subclass of prefrontal gamma-aminobutyric acid axon terminals are selectively altered in schizophrenia. Proc Natl Acad Sci U S A. 1998; 95(9): 5341-5346.
80. Pierri JN, Chaudry AS, Woo TU, Lewis DA. Alterations in chandelier neuron axon terminals in the prefrontal cortex of schizophrenic subjects. Am J Psychiatry. 1999; 156(11): 1709-1719.
81. Kawaguchi Y, Hama K. Fast-spiking non-pyramidal cells in the hippocampal CA3 region, dentate gyrus and subiculum of rats. Brain Res. 1987; 425(2): 351-355.
82. Gonzalez-Burgos G, Lewis DA. GABA neurons and the mechanisms of network oscillations: implications for understanding cortical dysfunction in schizophrenia. Schizophr Bull. 2008; 34(5): 944-961.
83. Lodge DJ, Behrens MM, Grace AA. A loss of parvalbumin-containing interneurons is associated with diminished oscillatory activity in an animal model of schizophrenia. J Neurosci. 2009; 29(8): 2344-2354.
84. Tsuang MT, Gilbertson MW, Faraone SV. The genetics of schizophrenia. Current knowledge and future directions. Schizophr Res. 1991; 4(2): 157-171.
85. Tsuang MT, Stone WS, Faraone SV. Schizophrenia: family studies and treatment of spectrum disorders. Dialogues in Clinical Neuroscience. 2000; 2(4): 381-391.
86. Cardno AG, Jones LA, Murphy KC, etal. Dimensions of psychosis in affected sibling pairs. Schizophr Bull. 1999; 25(4): 841-850.
87. Kendler KS. Twin studies of psychiatric illness. Current status and future directions. Arch Gen Psychiatry. 1993; 50(11): 905-915.
88. Sullivan PF, Kendler KS, Neale MC. Schizophrenia as a complex trait: evidence from a meta-analysis of twin studies. Arch Gen Psychiatry. 2003; 60(12): 1187-1192.
89. McGuffin P, Owen MJ, Farmer AE. Genetic basis of schizophrenia. Lancet. 1995; 346(8976): 678-682.
90. Millar JK, Wilson-Annan JC, Anderson S, etal. Disruption of two novel genes by a translocation co-segregating with schizophrenia. Hum Mol Genet. 2000; 9(9): 1415-1423.
91. Debono R, Topless R, Markie D, Black MA, Merriman TR. Analysis of the DISC1 translocation partner (11q14.3) in genetic risk of schizophrenia. Genes Brain Behav. 2012; 11(7): 859-863.
92. Harrison PJ, Weinberger DR. Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence. Mol Psychiatry. 2005; 10(1): 40-68.
93. Craddock N, O'Donovan MC, Owen MJ. The genetics of schizophrenia and bipolar disorder: dissecting psychosis. J Med Genet. 2005; 42(3): 193-204.
94. Harrison PJ, Owen MJ. Genes for schizophrenia? Recent findings and their pathophysiological implications. Lancet. 2003; 361(9355): 417-419.
95. Stefansson H, Sigurdsson E, Steinthorsdottir V, etal. Neuregulin 1 and susceptibility to schizophrenia. Am J Hum Genet. 2002; 71(4): 877-892.
96. Hosak L, Silhan P, Hosakova J. Genomic copy number variations: A breakthrough in our knowledge on schizophrenia etiology? Neuro Endocrinol Lett. 2012; 33(2): 183-190.
97. Jia P, Wang L, Meltzer HY, Zhao Z. Common variants conferring risk of schizophrenia: a pathway analysis of GWAS data. Schizophr Res. 2010; 122(1-3): 38-42.
98. Alkelai A, Lupoli S, Greenbaum L, etal. Identification of new schizophrenia susceptibility loci in an ethnically homogeneous, family-based, Arab-Israeli sample. FASEB J. 2011; 25(11): 4011-4023.
99. Alkelai A, Lupoli S, Greenbaum L, etal. DOCK4 and CEACAM21 as novel schizophrenia candidate genes in the Jewish population. Int J Neuropsychopharmacol. 2012; 15(4): 459-469.
100. Athanasiu L, Mattingsdal M, Kähler AK, etal. Gene variants associated with schizophrenia in a Norwegian genome-wide study are replicated in a large European cohort. J Psychiatr Res. 2010; 44(12): 748-753.
101. Gershon ES, Alliey-Rodriguez N, Liu C. After GWAS: searching for genetic risk for schizophrenia and bipolar disorder. Am J Psychiatry. 2011; 168(3): 253-256.
102. Brown R, Colter N, Corsellis JA, etal. Postmortem evidence of structural brain changes in schizophrenia. Differences in brain weight, temporal horn area, and parahippocampal gyrus compared with affective disorder. Arch Gen Psychiatry. 1986; 43(1): 36-42.
103. Bogerts B, Falkai P, Greve B, Schneider T, Pfeiffer U. The neuropathology of schizophrenia: past and present. J Hirnforsch. 1993; 34(2): 193-205.
104. Bogerts B, Lieberman JA, Ashtari M, etal. Hippocampus-amygdala volumes and psychopathology in chronic schizophrenia. Biol Psychiatry. 1993; 33(4): 236-246.
105. Gonzalez-Burgos G, Hashimoto T, Lewis DA. Alterations of cortical GABA neurons and network oscillations in schizophrenia. Curr Psychiatry Rep. 2010; 12(4): 335-344.
106. Hill K, Mann L, Laws KR, Stephenson CM, Nimmo-Smith I, McKenna PJ. Hypofrontality in schizophrenia: a meta-analysis of functional imaging studies. Acta Psychiatr Scand. 2004; 110(4): 243-256.
107. Moore H, Jentsch JD, Ghajarnia M, Geyer MA, Grace AA. A neurobehavioral systems analysis of adult rats exposed to methylazoxymethanol acetate on E17: implications for the neuropathology of schizophrenia. Biol Psychiatry. 2006; 60(3): 253-264.
108. Lodge DJ, Grace AA. Gestational methylazoxymethanol acetate administration: a developmental disruption model of schizophrenia. Behav Brain Res. 2009; 204(2): 306-312.
109. Bayer SA, Altman J, Russo RJ, Zhang X. Timetables of neurogenesis in the human brain based on experimentally determined patterns in the rat. Neurotoxicology. 1993; 14(1): 83-144.
110. Lodge DJ, Grace AA. Aberrant hippocampal activity underlies the dopamine dysregulation in an animal model of schizophrenia. J Neurosci. 2007; 27(42): 11424-11430.
111. Perez SM, Lodge DJ. Aberrant dopamine D2-like receptor function in a rodent model of schizophrenia. J Pharmacol Exp Ther. 2012; 343(2): 288-295.
112. Perez SM, Shah A, Asher A, Lodge DJ. Hippocampal deep brain stimulation reverses physiological and behavioural deficits in a rodent model of schizophrenia. Int J Neuropsychopharmacol. 2013; 16(6): 1331-1339.
113. Perez SM, Lodge DJ. Hippocampal interneuron transplants reverse aberrant dopamine system function and behavior in a rodent model of schizophrenia. Mol Psychiatry. 2013; 18(11): 1193-1198.
114. Floresco SB, Todd CL, Grace AA. Glutamatergic afferents from the hippocampus to the nucleus accumbens regulate activity of ventral tegmental area dopamine neurons. J Neurosci. 2001; 21(13): 4915-4922.
115. Floresco SB, West AR, Ash B, Moore H, Grace AA. Afferent modulation of dopamine neuron firing differentially regulates tonic and phasic dopamine transmission. Nat Neurosci. 2003; 6(9): 968-973.
116. Grace AA, Bunney BS. Intracellular and extracellular electrophysiology of nigral dopaminergic neurons-1. Identification and characterization. Neuroscience. 1983; 10(2): 301-315.
117. Lodge DJ, Grace AA. The hippocampus modulates dopamine neuron responsivity by regulating the intensity of phasic neuron activation. Neuropsychopharmacology. 2006; 31(7): 1356-1361.
118. Schobel SA, Lewandowski NM, Corcoran CM, etal. Differential targeting of the CA1 subfield of the hippocampal formation by schizophrenia and related psychotic disorders. Arch Gen Psychiatry. 2009; 66(9): 938-946.
119. Heckers S, Rauch SL, Goff D, etal. Impaired recruitment of the hippocampus during conscious recollection in schizophrenia. Nat Neurosci. 1998; 1(4): 318-323.
120. Lipska BK, Jaskiw GE, Weinberger DR. Postpubertal emergence of hyperresponsiveness to stress and to amphetamine after neonatal excitotoxic hippocampal damage: a potential animal model of schizophrenia. Neuropsychopharmacology. 1993; 9(1): 67-75.
121. Swerdlow NR, Halim N, Hanlon FM, Platten A, Auerbach PP. Lesion size and amphetamine hyperlocomotion after neonatal ventral hippocampal lesions: more is less. Brain Res Bull. 2001; 55(1): 71-77.
122. Zhang ZJ, Reynolds GP. A selective decrease in the relative density of parvalbumin-immunoreactive neurons in the hippocampus in schizophrenia. Schizophr Res. 2002; 55(1-2): 1-10.
123. Shah A, Lodge DJ. A loss of hippocampal perineuronal nets produces deficits in dopamine system function: relevance to the positive symptoms of schizophrenia. Transl Psychiatry. 2013; 3: e215.
124. Gill KM, Lodge DJ, Cook JM, Aras S, Grace AA. A novel α5GABA(A)R-positive allosteric modulator reverses hyperactivation of the dopamine system in the MAM model of schizophrenia. Neuropsychopharmacology. 2011; 36(9): 1903-1911.
125. Gastambide F, Cotel MC, Gilmour G, O'Neill MJ, Robbins TW, Tricklebank MD. Selective remediation of reversal learning deficits in the neurodevelopmental MAM model of schizophrenia by a novel mGlu5 positive allosteric modulator. Neuropsychopharmacology. 2012; 37(4): 1057-1066.
126. Volz A, Khorsand V, Gillies D, Leucht S. Benzodiazepines for schizophrenia. Cochrane Database Syst Rev. 2007: CD006391.
127. Tiihonen J, Suokas JT, Suvisaari JM, Haukka J, Korhonen P. Polypharmacy with antipsychotics, antidepressants, or benzodiazepines and mortality in schizophrenia. Arch Gen Psychiatry. 2012; 69(5): 476-483.
128. McKernan RM, Whiting PJ. Which GABAA-receptor subtypes really occur in the brain? Trends Neurosci. 1996; 19(4): 139-143.
129. Quirk K, Blurton P, Fletcher S, etal. [3H]L-655, 708, a novel ligand selective for the benzodiazepine site of GABAA receptors which contain the alpha 5 subunit. Neuropharmacology. 1996; 35(9-10): 1331-1335.
130. Pritchett DB, Sontheimer H, Shivers BD, etal. Importance of a novel GABAA receptor subunit for benzodiazepine pharmacology. Nature. 1989; 338(6216): 582-585.
131. Heldt SA, Ressler KJ. Forebrain and midbrain distribution of major benzodiazepine-sensitive GABAA receptor subunits in the adult C57 mouse as assessed with in situ hybridization. Neuroscience. 2007; 150(2): 370-385.
132. Ramos B, Lopez-Tellez JF, Vela J, etal. Expression of alpha 5 GABAA receptor subunit in developing rat hippocampus. Brain Res Dev Brain Res. 2004; 151(1-2): 87-98.
133. Mayberg HS, Lozano AM, Voon V, etal. Deep brain stimulation for treatment-resistant depression. Neuron. 2005; 45(5): 651-660.
134. Greenberg BD, Pinto A, Mancebo M, Eisen J, Rasmussen SA. Obsessive-compulsive disorder: recognition across medical settings, and treatments from behavior therapy to neurosurgery. Med Health R I. 2006; 89(5): 162-165.
135. Benabid AL, Pollak P, Gervason C, etal. Long-term suppression of tremor by chronic stimulation of the ventral intermediate thalamic nucleus. Lancet. 1991; 337(8738): 403-406.
136. Wyckhuys T, De Smedt T, Claeys P, etal. High frequency deep brain stimulation in the hippocampus modifies seizure characteristics in kindled rats. Epilepsia. 2007; 48(8): 1543-1550.
137. Boon P, Vonck K, De Herdt V, etal. Deep brain stimulation in patients with refractory temporal lobe epilepsy. Epilepsia. 2007; 48(8): 1551-1560.
138. Grace AA, Floresco SB, Goto Y, Lodge DJ. Regulation of firing of dopaminergic neurons and control of goal-directed behaviors. Trends Neurosci. 2007; 30(5): 220-227.